{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216743","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2026-05-11T20:05:34+00:00","discovered_at":"2026-05-11T20:08:00.325450+00:00","generated_at":"2026-05-11T22:49:04.504915+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aura Q1 net loss $33.7M; Phase 3 CoMpass enrollment mid-2026; new CEO appointed","bullets":["Net loss of $33.7M in Q1 2026; R&D expenses $28.0M (up from $23.3M) reflecting Phase 3 costs.","Phase 3 CoMpass trial in early choroidal melanoma enrollment expected to complete mid-2026; topline data in 2H 2027.","Natalie Holles appointed CEO and President effective April 30, 2026, succeeding founder Elisabet de los Pinos.","Completed $299M equity offering (net ~$280.8M); used $39M to repurchase shares from Matrix Capital; cash into 2H 2028.","Pipeline: Phase 2 choroidal metastases data in 2026; Phase 1 ocular cancer PoC data in 2026; bladder cancer data mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216743","json":"https://secwatch.observer/filing/0001193125-26-216743.json","markdown":"https://secwatch.observer/filing/0001193125-26-216743.md","text":"https://secwatch.observer/filing/0001193125-26-216743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526216743/0001193125-26-216743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526216743/aura-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:49:04.504915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1b53ce47ac0aaaae66d7d45facb2b5f28ec0291","claim":"Aura Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income $33.7 million.","evidence_excerpt":"Net loss for the three months ended March 31, 2026, was $33.7 million, compared to $27.5 million for the three months ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526216743/0001193125-26-216743-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"$33.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}